An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

199754 citationsJournal Article

Authors

paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

Good health and well-being

Published in: Anti-Cancer Drugs

Volume 8, Issue 7, pp. 657-661

Field-Weighted Citation Impact: 1.17